Article
p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma.
Medical and pediatric oncology - 1 Dec 2000
Keshelava N, Zuo J J, Waidyaratne N S, Triche T J, Reynolds C P
Abstract excerpt
BACKGROUND: Neuroblastomas often acquire sustained drug resistance during therapy. Sensitivities to carboplatin, etoposide, or melphalan were determined for 18 neuroblastoma cell lines; eight were sensitive and ten were resistant. As p53 mutations are rare in neuroblastomas studied at diagnosis, we determined if acquired p53 mutations and loss of function conferred multidrug resistance. RESULTS: Loss of p53...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.